Relmacabtagene autoleucel for relapsed or refractory follicular lymphoma: two-year follow-up of the phase 2 RELIANCE study
The multicenter phase 2 RELIANCE study in China evaluated relmacabtagene autoleucel (relma-cel) for relapsed or refractory follicular lymphoma after at least 3 previous lines of therapy in 60% of patients. Two-year follow-up results of the study have now been published. Two-year progression-free survival and overall survival rates were 80.3% and 100%, respectively. During the 90-day treatment-emergent period (n=28), no patients had cytokine release syndrome of grade ≥ 3, and neurological toxicity of grade ≥ 3 occurred in only one patient treated with 100 x 106 CAR T cells. Neutropenia (39.3%) was the most common grade ≥ 3 treatment-emergent adverse event. There were no AEs leading to death. The authors conclude that relma-cel demonstrated durable remission and manageable safety during 2-year follow-up in patients with R/R FL.